Capivasertib PFS in HR-positive breast cancer
8 December 2022 13:30 GMT Capivasertib plus Faslodex reduced the risk of disease progression ordeath by 40% versus Faslodex in advanced HR-positive breast cancer CAPItello-291 Phase III trial results presented at SABCS 2022show potential of capivasertib as first-in-class AKT inhibitor Detailed results from the CAPItello-291 Phase III trial showed AstraZeneca's capivasertib in combination with Faslodex (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo plus Faslodex in patients with